Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours

Anhydrous sodium thiosulfate (Pedmarqsi, Norgine) is indicated for 'the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours'.

The dosage schedule is available in the summary of product characteristics for anhydrous sodium thiosulfate.

The list price for anhydrous sodium thiosulfate is £8,277.71 per 8‑g vial. The company has a commercial arrangement. This makes anhydrous sodium thiosulfate available to the NHS with a discount. The size of the discount is commercial in confidence.